PRGO (Perrigo) Multiplikator Forward P/S
The over-the-counter market is characterized by aggressive dumping, which is confirmed by the change in the projected P/S for Perrigo Company plc (PRGO). The value of 0.60 corresponds to the current metric, reflecting pressure from competition with private labels and raw material issues. Additionally, profitability is impacted by restructuring challenges in pediatric nutrition and potential batch recalls, although a resilient core portfolio mitigates the decline in demand.
Rincian analitis perusahaan Perrigo Company plc
- rega pasar lan target rega analis:
- indikator valuasi pasar bisnis:
- statistik nilai buku emiten:
- data utang lan likuiditas:
Total Utang marang Modal Perrigo Company plc|PRGO - Rasio tanggungan utang jangka dawa marang modal|Utang jangka cendhak marang modal Perrigo Company plc|PRGO - Tanggungan utang total perusahaan|Rasio utang marang kapitalisasi buku Perrigo Corp|PRGO - Utang jangka dawa|Kewajiban jangka cendhak perusahaan Perrigo|Rasio cepet perrigo.com
- data bathi bisnis lan rasio investasi:
PRGO - Penghasilan resik|Bathi sing dikarepake Perrigo Company plc|PRGO - Kapitalisasi marang bathi|Rega marang bathi mangsa ngarep Perrigo Company|PRGO - Pangali rega marang bathi tumrap wutah|Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Perrigo Corp|PRGO - Bathi sadurunge ngurangi bunga, pajak, penyusutan, lan amortisasi|Bathi resik saben saham (EPS TTM) Perrigo|PRGO - Bathi resik saben saham (EPS TTM)|Wutah bathi saben saham taun-ka-taun sajrone rolas wulan pungkasan perrigo.com|PRGO - Wutah bathi saben saham ing taun iki|Prakiraan wutah bathi saben saham kanggo taun ngarep Perrigo Company plc
- statistik dodolan lan pendapatan perusahaan:
Analisis dhasar perusahaan:PRGO (Perrigo)
The restructuring of Perrigo Company plc (PRGO) and its focus on high-margin consumer brands make the analysis of sales efficiency critically important. This indicator compares the current market value of the business with expected annual sales volume, allowing for an assessment of the asset's overbought status. Monitoring the projected price-to-sales ratio helps identify the risk of a correction in a timely manner if forecasted revenue targets are not met.
Analisis pesaing
Rasio rega marang prakiraan pendapatan Haleon HLN|KVUE (Kenvue Inc) - Rega mangsa ngarep marang pendapatan|Verona Pharma Corp - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Jyong Bio|Ligand Pharmaceuticals (LGND) - Rasio rega marang prakiraan pendapatan|amneal.com - Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan Alvotech SA|LQDA: Rega forward marang dodolan|Multiplikator Forward P/S GLPG|Rasio kapitalisasi marang dodolan sing dikarepake ANI Pharmaceuticals Corp|Multiplikator Forward P/S MNKD (MannKind Corporation)|Prakiraan rega marang pendapatan amphastar.com|PCRX - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep ARS Pharmaceuticals Inc|TBPH (Theravance) - Multiplikator forward rega marang pendapatan|Aquestive Corp - Rega forward marang dodolan|SCPH (scPharmaceuticals, Inc.) - Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan Tectonic (TECX)|Rasio rega marang prakiraan pendapatan Tonix Pharmaceuticals Holding Corp. (TNXP)|SXTC - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|Rasio rega marang prakiraan pendapatan Eupraxia Pharmaceuticals Inc. EPRX|BHST - Multiplikator forward rega marang pendapatan|EXOZ - Rasio rega marang prakiraan pendapatan|Rega mangsa ngarep marang pendapatan ORMP|ENTX: Multiplikator Forward P/S|MindWalk Holdings, Inc. (HYFT) - Multiplikator Forward P/S|Rasio rega marang prakiraan pendapatan ABVC BioPharma Inc|Kapitalisasi marang prakiraan pendapatan CPIX (Cumberland Corp)|Multiplikator forward rega marang pendapatan QNTM (Quantum BioPharma Ltd)|FGEN - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|Telomir Pharmaceuticals, Inc. - Multiplikator forward rega marang pendapatan|Rega forward marang dodolan RANI|SNYR - Rasio rega marang prakiraan pendapatan|Rega mangsa ngarep marang pendapatan RLYB|lexariabioscience.com (LEXX) - Rasio rega marang prakiraan pendapatan|PULM (pulmatrix.com) - Rasio rega marang prakiraan pendapatan|PTHL (Pheton Holdings Limited) - Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan Aptorum (APM)|Rasio rega marang prakiraan pendapatan Lyra Therapeutics, Inc (LYRA)|IBO: Rega mangsa ngarep marang pendapatan|Rasio rega marang prakiraan pendapatan TNF Pharmaceuticals, Inc. TNFA|Rega forward marang dodolan YCBD|PainReform - Multiplikator Forward P/S|Prakiraan rega marang pendapatan Altamira Therapeutics (CYTO)|Lipella (LIPO) - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep OptiNose Corp (OPTN)|Rasio rega marang prakiraan pendapatan Pieris Pharmaceuticals|procapsgroup.com - Rega mangsa ngarep marang pendapatan|Multiplikator Forward P/S PTPI|QLI (Qilian International Holding Group) - Rega forward marang dodolan|Multiplikator Forward P/S SLRN (ACELYRIN, Inc.)|Multiplikator Forward P/S TFF Pharmaceuticals, Inc TFFP
